The Peter Attia Drive Podcast: How Modern Drugs Really Get Made

SPEAKER_1 (0:01)

When modern drug development works, it looks almost magical. But there's so much science, regulation, and economics underneath every successful therapy. Peter Attia's recent conversation with Lloyd Klickstein really pulls back the curtain on this process. I loved how Lloyd traced his own journey into this world. He started with plans for medical school, then pivoted to an MD PhD, went into rheumatology, and spent years running an NIH funded lab before making the leap to Novartis. That move brought him into translational medicine, where the whole goal is connecting basic science to real clinical needs. Right, and Peter asked the key question about the black box of drug discovery. Lloyd's answer was fascinating. He stressed that developers don't begin with chemistry, they start with patients and unmet need. That patient-first approach really shapes everything. He also drew this sharp line between incremental and quantum advances. Incremental progress might mean turning an injectable into an oral drug, which is useful but not revolutionary. The harder work is creating treatments for conditions that have no established code or accepted pathway. That requires serious regulatory strategy and a willingness to accept failure. But that's where the biggest value to society lives, according to Lloyd. Take sarcopenia and frailty in older adults. He saw the devastating reality as a rheumatologist, including the mortality rates of frail elders needing nursing home care. His team built programs to study muscle disease and falls.

The falls measurement story is such a reality check though. They designed a pendant device and tested it in elderly residents, but Lloyd admits the device was awful. It captured only a small fraction of real falls. The project stopped because the outcome couldn't be measured well enough. That's the kind of failure that never makes headlines. But it set the stage for deeper work on muscle biology and bimagrumab. Lloyd explained how myostatin, activins, and the TGF beta pathway regulate muscle growth, and why blocking the receptor matters more than chasing one ligand. The early rodent work created these Arnold Schwarzenegger mice, but human biology turned out much less dramatic. In people, the drug increased muscle mass, yet performance gains were limited. It proved again that human and mouse biology aren't the same.

Then there's the whole journey from antibody discovery to IND enabling studies, toxicology, GMP manufacturing, and Phase 1 dosing. Companies have to worry about developability, immunogenicity, and whether toxic effects are reversible. The cost can reach billions once late stage studies begin. The obesity chapter is where things get really exciting. After semaglutide changed the market, bimagrumab found new life in combination studies.

The BELIEVE trial showed major fat loss with preserved lean mass.

Lloyd talks about a future of induction and maintenance of remission for obesity.

Though they saw an LDL rise that appears on target. Every benefit comes with tradeoffs. Lloyd's closing thoughts on selective mTOR inhibition and cancer prevention really capture his philosophy:

target the pathways behind the biggest causes of morbidity and mortality, then build therapies that are practical, measurable, and safe. It's a disciplined, candid look at how real drugs are made.